





INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

| | | | | | | | |
|---|--|-------------|---------------|---|-----------|----------------------------|--|
| Atty. Docket No. 01975.0024-00 | | | | Serial No. 09/555,139 | | | |
| Applicant Etienne AGSTERIBBE et al. | | | | | | | |
| Filing Date May 25, 2000 | | | | Group: 1645 | | | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| Examiner Initial* | Document Number | Date | Name | Class | Sub Class | Filing Date If Appropriate | |
| | | | | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | |
| | Document Number | Date | Country | Class | Sub Class | Translation Yes or No | |
| | 1 498 261 | 18 Jan 1978 | Great Britain | | | | |
| | | | | | | | |
| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | | |
|  | Hirabayashi et al., "Comparison of intranasal inoculation of influenza HA vaccine combined with cholera toxin B subunit with oral or parenteral vaccination," <i>Vaccine</i> 8:243-248 (1990). | | | | | | |
| | Kikuta et al., "Cross-protection against influenza B type virus infection by intranansal inoculation of the HA vaccines combined with cholera toxin B subunit," <i>Vaccine</i> 8:595-599 (1990). | | | | | | |
| | Tamura et al., "Cross-Protection Against Influenza Virus Infection Afforded By Trivalent Inactivated Vaccines Inoculated Intranasally With Cholera Toxin B Subunit," <i>J. Immunology</i> 3:981-988 (1992). | | | | | | |
| | Tamura et al., "Synergistic action of cholera toxin B subunit (and <i>Escherichia coli</i> heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine," <i>Vaccine</i> 12:419-426 (1994). | | | | | | |
| | Tamura et al., " <i>Escherichia coli</i> heat-labile enterotoxin B subunits supplemented with a trace amount of the holotoxin as an adjuvant for nasal influenza vaccine," <i>Vaccine</i> 12:1083-1089 (1994). | | | | | | |
| | Davenport et al., "Comparisons of serologic and febrile responses in humans to vaccination with influenza A viruses or their hemagglutinins," <i>J. Lab. & Clin. Med.</i> 63:5-13 (1964). | | | | | | |
| | Clancy, "Mucosal Vaccines for the Prevention of Influenza," <i>Drugs</i> 50:587-594 (1995). | | | | | | |
| | Katz et al., "Adjuvant Activity of the Heat-Labile Enterotoxin from Enterotoxigenic <i>Escherichia coli</i> for Oral Administration of Inactivated Influenza Virus Vaccine," <i>J. Infect. Dis.</i> 175:352-363 (1997). | | | | | | |
| | Vieira et al., "The pUC plasmids, an M13mp7-derived system for insertion mutagenesis and sequencing with synthetic universal primers," <i>Gene</i> 19:259-268 (1982). | | | | | | |
| | De Haan et al., "Mucosal immunogenicity of the <i>Escherichia coli</i> heat-labile enterotoxin: role of the A subunit," <i>Vaccine</i> 14:260-266 (1996). | | | | | | |
| Examiner  | | | | Date Considered 1/8/02 | | | |
| *Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | | | |
| Form PTO 1449 | | | | Patent and Trademark Office - U.S. Department of Commerce | | | |

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

| | | | | | | | |
|---|--|-----------------|------|---|-------|-----------|----------------------------|
| Atty. Docket No. 01975.0024-00 | | | | Serial No. 09/555,139 | | | |
| Applicant Etienne AGSTERIBBE et al. | | | | | | | |
| Filing Date May 25, 2000 | | | | Group: 1645 | | | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| Examiner Initial* | | Document Number | Date | Name | Class | Sub Class | Filing Date If Appropriate |
| | | | | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | |
| | | Document Number | Date | Country | Class | Sub Class | Translation Yes or No |
| | | | | | | | |
| | | | | | | | |
| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | | |
|  | Dallas et al., "Cistrons Encoding <i>Escherichia coli</i> Heat-Labile Toxin," <i>J. Bacteriol.</i> 139:850-858 (1979). | | | | | | |
| | Van der Linden et al., "Cytoplasmic high-level expression of a soluble, enzymatically active form of the <i>Escherichia coli</i> penicillin-binding protein 5 and purification by dye chromatography," <i>Eur. J. Biochem.</i> 204:197-202 (1992). | | | | | | |
| | Uesaka et al., "Simple method of purification of <i>Escherichia coli</i> heat-labile enterotoxin and cholera toxin using immobilized galactose," <i>Microb. Path.</i> 16:71-76 (1994). | | | | | | |
| | Chaloupka et al., "Comparative Analysis of Six European Influenza Vaccines," <i>Eur. J. Microbiol. Infect. Dis.</i> 15:121-127 (1996). | | | | | | |
| | Wood et al., "An improved single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen: application for potency determinations of inactivated whole virus and subunit vaccines," <i>J. Biol. Stand.</i> 5:237-247 (1977). | | | | | | |
| | Hashigucci et al., "Antibody responses in volunteers induced by nasal influenza vaccine combined with <i>Escherichia coli</i> heat-labile enterotoxin B subunit containing a trace amount of the holotoxin," <i>Vaccine</i> 14:113-119 (1996). | | | | | | |
| | Nashar et al., "Current progress in the development of the B subunits of cholera toxin and <i>Escherichia coli</i> heat-labile enterotoxin as carriers for the oral delivery of heterologous antigens and epitopes," <i>Vaccine</i> 11:235-240 (1993). | | | | | | |
| | Verweij et al., "Mucosal immunoadjuvant activity of recombinant <i>Escherichia coli</i> heat-labile enterotoxin and its B subunit: Induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with influenza virus surface antigen," <i>Vaccine</i> 16:2069-2076 (1998). | | | | | | |
| Examiner  | | | | Date Considered 1/8/02 | | | |
| *Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | | | |
| Form PTO 1449 | | | | Patent and Trademark Office - U.S. Department of Commerce | | | |